• Synergistic Blockade of OXPHOS via LRPPRC Inhibition and Das

  2026-06-12

  This study identifies a dual-genome approach to disrupt mitochondrial oxidative phosphorylation (OXPHOS) in cancer by combining LRPPRC inhibition with dasatinib. The synergistic effect, validated through high-throughput screening and mechanistic analysis, highlights a promising strategy for targeting OXPHOS-dependent tumors and advances the rationale for tailored combination therapies.

• O-GlcNAcylation Directs Wnt-Induced Bone Formation via Glyco

  2026-06-11

  This study uncovers how Wnt3a-driven O-GlcNAcylation at PDK1 Ser174 orchestrates glycolytic reprogramming essential for bone formation and fracture healing. These insights elucidate the metabolic mechanisms underpinning Wnt signaling in osteoblast differentiation, informing future approaches to modulate bone anabolism.

• DAF-2 Diacetate: Precision Live-Cell Nitric Oxide Imaging

  2026-06-11

  DAF-2 diacetate enables unparalleled sensitivity and stability for live-cell nitric oxide imaging and in vivo detection. Drawing from recent insights into sulfur-regulated nodule senescence, this article delivers actionable workflows, troubleshooting, and optimization strategies for maximizing NO bioimaging with APExBIO’s trusted probe.

• 5-Azacytidine in Epigenetic Cancer Modeling: Mechanisms & In

  2026-06-10

  Explore the multifaceted role of 5-Azacytidine as a DNA demethylation agent in advanced cancer modeling. This article uniquely integrates recent mechanistic insights and protocol strategies for translational research.

• A-1331852: Precision BCL-XL Inhibition for Translational Apo

  2026-06-10

  This thought-leadership article examines the pivotal role of A-1331852, a next-generation BCL-XL inhibitor from APExBIO, in enabling translational advances in apoptosis and cancer research. By integrating mechanistic insights, recent evidence from glioblastoma studies, and practical workflow guidance, we chart a strategic roadmap for researchers seeking to harness BCL-XL–BIM complex disruption for both robust apoptosis assays and preclinical therapy development.

• Data-Driven Design of Kinase Inhibitor Libraries for Cancer

  2026-06-09

  Moret et al. (2019) present a systematic cheminformatics approach to analyzing and optimizing small-molecule libraries, focusing on binding selectivity and target coverage. Their methodology enables the creation of compact, highly selective kinase inhibitor collections, enhancing toolkits for studying oncogenic signaling and drug response mechanisms.

• tFUS Suppresses Stroke Neuroinflammation via Nespas/miR-383-

  2026-06-09

  This study uncovers how transcranial focused ultrasound stimulation (tFUS) mitigates NLRP3-mediated neuroinflammation after ischemic stroke by upregulating the Nespas/miR-383-3p/SHP2 pathway in microglia. The findings clarify a mechanistic link between noninvasive neuromodulation and SHP2-regulated inflammatory signaling, providing a platform for future research on targeted interventions.

• 0.4% Trypan Blue Solution: Reliable Cell Viability Measureme

  2026-06-08

  0.4% Trypan Blue Solution addresses the need for direct, reagent-driven discrimination of live and dead cells during cell viability measurement and cytotoxicity assays. Intended for research applications, it should not be used for diagnostic or clinical purposes.

• Placebo-Controlled Evidence for Mianserin HCl in Depression

  2026-06-08

  A rigorous double-blind, placebo-controlled trial established the antidepressant efficacy of Mianserin HCl, highlighting its rapid impact on both mood and sleep quality in severely depressed female inpatients. The study's protocol and findings provide a robust clinical foundation for further psychiatric disorder research and serotonin receptor modulation studies.

• Leveraging 5-Azacytidine (SKU A1907) for Reliable Epigenetic

  2026-06-07

  This article addresses key experimental challenges in cell viability and DNA methylation studies, illustrating how 5-Azacytidine (SKU A1907) provides reproducible, literature-backed solutions. Through scenario-driven Q&A, it guides biomedical researchers and lab technicians in optimizing workflows, interpreting data, and selecting dependable reagents for epigenetic and oncology research.

• Dicloxacillin’s Intra- and Extracellular Efficacy Against MS

  2026-06-06

  This study rigorously evaluates the intra- and extracellular activities of dicloxacillin (DCX) against methicillin-sensitive Staphylococcus aureus (MSSA) using both in vitro and in vivo models. The research establishes that the minimum inhibitory concentration (MIC) is a reliable predictor of DCX efficacy in both cellular environments and highlights the importance of maintaining free drug concentrations above MIC for optimal antibacterial action.

• Ziprasidone Augmentation with Escitalopram in Anxious Depres

  2026-06-05

  The referenced study rigorously evaluated ziprasidone augmentation in patients with major depressive disorder (MDD) exhibiting anxious versus nonanxious features, all treated with escitalopram. Its nuanced moderator analysis advances understanding of antidepressant and anxiolytic response heterogeneity, informing both clinical trial design and preclinical modeling of serotonergic signaling.

• Novel Gemini QACs: Broad-Spectrum Antimicrobial Innovation

  2026-06-05

  This study reports the synthesis and characterization of sixteen gemini quaternary ammonium compounds as advanced derivatives of octenidine dihydrochloride. Several compounds demonstrated improved solubility, reduced cytotoxicity, and enhanced broad-spectrum antimicrobial, antifungal, and virucidal activities, offering promising alternatives for antiseptic research applications.

• NSC 87877 (SKU A4544): Shp2 Inhibitor Solutions for Reliable

  2026-06-04

  This article offers a scenario-driven guide to overcoming common challenges in cell viability, proliferation, and cytotoxicity assays with NSC 87877 (SKU A4544). Drawing on validated protocols and quantitative data, it demonstrates how this Shp2 inhibitor from APExBIO ensures reproducible, data-backed results for biomedical researchers. The piece is tailored for scientists seeking evidence-based best practices in kinase and phosphatase pathway interrogation.

• MALAT1-miR-125b-STAT3 Axis Controls PCT Expression in Sepsis

  2026-06-04

  This study uncovers a mechanistic pathway in which the long noncoding RNA MALAT1 upregulates procalcitonin (PCT) expression in sepsis by modulating the miR-125b/STAT3 axis. The findings provide critical insight into sepsis biomarker regulation and reveal new potential targets for diagnostic and therapeutic strategies.

553 records 15/37 page Previous Next First page 上5页 1112131415 下5页 Last page